NYSE:BCR - C R Bard Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $331.24 0.00 (0.00 %) (As of 07/17/2018 05:27 AM ET)Previous Close$331.24Today's Range$331.24 - $331.2452-Week Range$222.42 - $337.73VolumeN/AAverage Volume679,456 shsMarket Capitalization$24.14 billionP/E RatioN/ADividend Yield0.23%Beta0.52 Company ProfileFinancialsAnalyst RatingsDividend HistoryEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email C. R. Bard, Inc. (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis. Its vascular products cover a range of minimally invasive devices for the treatment of peripheral vascular disease and end-stage renal disease. Its urology products include basic urology drainage products, fecal and urinary continence products, urological specialty products and Targeted Temperature Management products. Its oncology products cover a range of devices used in the treatment and management of various cancers, and other diseases and disorders. Its surgical specialty products include implanted patches and fixation devices for hernia and soft tissue repairs. Receive BCR News and Ratings via Email Sign-up to receive the latest news and ratings for BCR and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSE Industry N/A Sub-IndustryHealth Care Equipment SectorN/A SymbolNYSE:BCR CUSIP06738310 Webwww.crbard.com Phone+1-908-2778000 Debt Debt-to-Equity Ratio0.57 Current Ratio1.72 Quick Ratio1.37 Price-To-Earnings Trailing P/E RatioN/A Forward P/E Ratio27.86 P/E Growth2.53 Sales & Book Value Annual Sales$3.71 billion Price / Sales6.50 Cash Flow$13.4760 per share Price / Cash24.58 Book Value$22.78 per share Price / Book14.54 Profitability EPS (Most Recent Fiscal Year)N/A Net Income$531.40 million Net Margins9.51% Return on Equity19.39% Return on Assets6.91% Miscellaneous Employees16,300 Outstanding Shares72,890,000Market Cap$24,140.00 C R Bard (NYSE:BCR) Frequently Asked Questions What is C R Bard's stock symbol? C R Bard trades on the New York Stock Exchange (NYSE) under the ticker symbol "BCR." How often does C R Bard pay dividends? What is the dividend yield for C R Bard? C R Bard declared a quarterly dividend on Wednesday, October 11th. Shareholders of record on Friday, December 8th will be given a dividend of $0.26 per share on Friday, December 29th. This represents a $1.04 dividend on an annualized basis and a yield of 0.31%. The ex-dividend date is Thursday, December 7th. View C R Bard's Dividend History. How were C R Bard's earnings last quarter? C R Bard Inc (NYSE:BCR) released its earnings results on Wednesday, October, 25th. The medical instruments supplier reported $3.02 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $2.96 by $0.06. The medical instruments supplier had revenue of $989.80 million for the quarter, compared to the consensus estimate of $990.64 million. C R Bard had a net margin of 9.51% and a return on equity of 19.39%. The firm's revenue for the quarter was up 5.1% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.64 EPS. View C R Bard's Earnings History. What price target have analysts set for BCR? 4 brokers have issued 1 year price targets for C R Bard's stock. Their forecasts range from $317.00 to $337.00. On average, they expect C R Bard's share price to reach $323.6667 in the next year. This suggests that the stock has a possible downside of 2.3%. View Analyst Ratings for C R Bard. What is the consensus analysts' recommendation for C R Bard? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for C R Bard in the last year. There are currently 4 hold ratings for the stock, resulting in a consensus recommendation of "Hold." What are Wall Street analysts saying about C R Bard stock? Here are some recent quotes from research analysts about C R Bard stock: 1. According to Zacks Investment Research, "In the last year, C. R. Bard has outperformed the broader industry trends with respect to price performance. Looking forward C. R. Bard is expected to benefit from the impending merger with Becton, Dickinson and Company, especially in the areas of medication management and infection prevention. The $24 billion transaction is expected to close in the fourth quarter of 2017. We believe the development will provide benefits to the combined entity and bolster its foothold in the global medical devices market. The growing adoption of Lutonix DCB is also expected to drive top-line growth in the coming quarters.However, a challenging Med-tech environment is a major concern. The company witnesses significant pricing pressure as well. Additionally, cutthroat competition in the hernia fixation and peripheral stent businesses are likely to dent growth. " (12/26/2017) 2. Needham & Company LLC analysts commented, "BCR’s 3Q17 revenue missed and EPS beat consensus and management raised its 2017 revenue and EPS guidance. Revenue growth slowed somewhat to 5.0% in 3Q17 from 6.4% in 2Q17 as three of four segments missed consensus. Revenue growth faced a 1.5% headwind, attributable to the impact from the hurricanes and a Surgical Sealant supply issue, both equally. We have maintained our revenue and EPS estimates." (10/26/2017) Who are C R Bard's key executives? C R Bard's management team includes the folowing people: Timothy M. Ring, Chairman of the Board, Chief Executive Officer (Age 59)John H. Weiland, President, Vice Chairman of the Board, Chief Operating Officer (Age 61)James C. Beasley, Group President (Age 53)Timothy P. Collins, Group President (Age 56)John P. Groetelaars, Group President (Age 50)Christopher S. Holland, Chief Financial Officer, Senior Vice President (Age 50)Samrat S. Khichi, Senior Vice President, General Counsel, Secretary (Age 49)John A. DeFord Ph.D., Senior Vice President - Science, Technology and Clinical Affairs (Age 55)Frank Lupisella Jr., Vice President, Controller (Age 56)Betty D. Larson, Vice President - Human Resources (Age 41) Has C R Bard been receiving favorable news coverage? Media coverage about BCR stock has been trending positive this week, Accern reports. The research firm scores the sentiment of media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. C R Bard earned a news impact score of 0.28 on Accern's scale. They also assigned news stories about the medical instruments supplier an impact score of 45.15 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near future. How do I buy shares of C R Bard? Shares of BCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is C R Bard's stock price today? One share of BCR stock can currently be purchased for approximately $331.24. How big of a company is C R Bard? C R Bard has a market capitalization of $24.14 billion and generates $3.71 billion in revenue each year. C R Bard employs 16,300 workers across the globe. How can I contact C R Bard? C R Bard's mailing address is 730 Central Ave, NEW PROVIDENCE, NJ 07974-1139, United States. The medical instruments supplier can be reached via phone at +1-908-2778000. MarketBeat Community Rating for C R Bard (NYSE BCR)Community Ranking: 1.8 out of 5 ()Outperform Votes: 291 (Vote Outperform)Underperform Votes: 521 (Vote Underperform)Total Votes: 812MarketBeat's community ratings are surveys of what our community members think about C R Bard and other stocks. Vote "Outperform" if you believe BCR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BCR will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/17/2018 by MarketBeat.com StaffFeatured Article: Should I invest in "strong buy" stocks?